This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John R. Gibson, MD
The Skin Department The London Hospital (Whitechapel) London El 1BB, England

Arch Dermatol. 1986;122(10):1098-1099.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The recent article by Vance et al¹ in the March issue of the ARCHIVES, concerning their success in treating condylomata acuminata, but reporting their disappointing results in treating verruca plantaris, using intralesional recombinant ₂-interferon therapy, prompted me to briefly present my experience in treating cutaneous nongenital viral warts (CNGVW) with intralesional human lymphoblastoid interferon a and to comment on the results reported by these authors.

Following an encouraging pilot study in patients with common and/or plantar viral warts,² a further exploratory study was established. The aims were to maximize the efficacy and patient acceptability of a treatment regimen based on intralesional injections of human lymphoblastoid interferon a (Wellferon, Wellcome Foundation Ltd) while minimizing the well-known potential for systemic toxicity possessed by the interferons.

Fully informed, adult patients of either sex with severe CNGVW present for a minimum of one year, and resistant to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?